MBX Biosciences, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company utilizes its proprietary Precision Endocrine Peptide (PEP™) platform to engineer product candidates that aim to deliver extended time action profiles, low peak to trough ratios, and less frequent dosing. Its lead candidate canvuparatide is a parathyroid hormone prodrug designed for once weekly treatment of chronic hypoparathyroidism. The obesity portfolio features MBX 4291 a GLP 1/GIP co agonist prodrug aimed at potential once monthly administration. A third program imapextide is a GLP 1 receptor antagonist being developed for once weekly therapy in post bariatric hypoglycemia. All candidates leverage the PEP™ platform to improve pharmaceutical properties such as stability, solubility, potency, and target selectivity.

MBX Biosciences, Inc. has not yet generated product revenue because its candidates remain in clinical development and have not received marketing approval. The company finances its research and development activities through capital raising including private placements, and public offerings. In addition it may receive milestone payments, and royalties under its license agreement with Indiana University Research and Technology Corporation. Future revenue is anticipated from product sales, licensing partnerships, or collaborations once its therapies achieve regulatory approval, and commercial launch. At present the firm relies on external contractors for manufacturing pre clinical, and clinical trial materials.

MBX Biosciences, Inc. positions itself as an innovator in peptide therapeutics by using its PEP™ platform to overcome limitations of existing peptide therapies such as short half life, and high peak to trough fluctuations. In the hypoparathyroidism market it competes with approved therapies like Ascendis Pharma's Yorvipath, and investigational agents from AstraZeneca and Extend Biosciences. For obesity its candidates face competition from established GLP 1 based agents such as Eli Lilly's tirzepatide, and Novo Nordisk's semaglutide as well as newer molecules from Amgen, Roche, Viking Therapeutics, and Zealand Pharma. In the post bariatric hypoglycemia space the company contrasts with Amylyx avexitide, and other emerging antagonists from Vogenx and Recordati. Competitive advantages include the proprietary PEP™ technology that enables dosing once weekly or once monthly, improved target selectivity, and a flatter pharmacokinetic profile. These attributes may enhance efficacy, improve tolerability, reduce dosing burden, and support better patient compliance compared with current standards of care.

MBX Biosciences, Inc. serves patients suffering from endocrine and metabolic disorders including those with hypoparathyroidism, obesity, and post bariatric hypoglycemia. Its customers are healthcare providers such as physicians, clinics, and hospitals that prescribe and administer its therapies. The company also engages with payers, and insurance entities that determine coverage, and reimbursement for its future products. Additionally MBX Biosciences interacts with patient advocacy groups, and medical societies to raise awareness of the diseases it targets. These relationships help inform clinical trial design, and facilitate access to appropriate patient populations.